Nuformix (LON:NFX ) has announced the appointment of Dr Anne Brindley as Chief Executive Officer "CEO" and Executive Director of the Company with immediate effect.

The group said Anne has over 30 years' experience in Big Pharma, Biotech and smaller R&D companies, with an international track record of leading organisations through strategic change and driving projects and portfolios through discovery and development to market. 

Anne was previously CEO of Advent Pharmaceuticals Pty Ltd, Melbourne, Australia, a specialty R&D company focused on generic inhaled products for global markets.

As Chief Executive of Advent Pharmaceuticals, Anne led a successful sale of the products and assets to AuroScience Pty Ltd, Melbourne, Australia, a wholly owned subsidiary of Aurobindo Pharma USA Inc. She subsequently became CEO of AuroScience Pty Ltd.
 
Prior to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (which is part of Johnson & Johnson, Inc).

Here, she was responsible for the operations of the group including discovery / development programmes in three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma, as well as out-licensing activities. Prior to this, Anne occupied the role of Vice President and Head of Inhalation Products. 

Anne's earlier career included roles as Executive Vice President, Pharmaceutical Development & Project Management at Skyepharma plc, a specialty pharma company developing innovative oral and inhalation products, and senior positions in Product Development at AstraZeneca PLC. Prior to this, Anne worked at GlaxoSmithKline plc.

“I am delighted to welcome Anne as the CEO of Nuformix. Anne has extensive expertise in small molecule R&D spanning discovery, early and late stage development, through to registration and commercialisation in respiratory and oncology therapy areas for both innovator and generic products,” said Dr Chris Blackwell, Non-Executive Chairman.

He added, “This wealth of relevant experience coupled with her leadership and Board experience will help the Company move forward with its strategic priorities.”

Commenting on her appointment, Dr Anne Brindley said, "Having worked in the pharma industry for over 30 years, I can see that Nuformix has assets and technology that have great potential and I intend to work with the Board to take these forward in development."

Shares in Nuformix have traded within a tight range of 2.70p and 3p over the past two weeks to open 7.41% higher this morning at 2.95p following the announcement.

Reasons to follow Nuformix

Nuformix is a pharmaceutical group which uses cocrystal technology to unlock the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis. 
 
The company announced its plans to raise around £0.65m at a price of 2.8p a share back in October 2020 in an effort to develop several of its assets to treat the effects of COVID-19.  
 
The proceeds will be used to maximise opportunities for the development pipeline, in particular for its lead asset, NXP002, which it believes could be used to treat hyperinflammation, a side effect seen in some patients suffering with severe COVID-19.  
 
It also believes NXP002 could be used in combination with existing marketed products in the treatment of idiopathic Pulmonary Fibrosis (“IPF”) a serious lung disease. In doing so, the group would be targeting the global IPF market which is valued at around US$2bn a year.  
 
The Board has prioritised this preclinical work alongside other IPF therapies because ‘it is likely that the adoption of new therapies for IPF will be on top of current standard of care.’  
  
The Company said that it plans to exploit the potential for licensing NXP002 across global markets, and in particular to continue to pursue licensing opportunities in the Asian market. It also added that it wants to 'exploit value’ from NXP001 outside the field of oncology.  
 
‘The Board is positive about the opportunities for the Group, in particular, for the development of certain assets for the treatment of Covid-19. Support for these efforts will require additional business development resources,’ the Company outlined to investors last month. 
 
For more news and updates on Nuformix: